Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4104
Abstract: 4104Background: There is currently no standard therapy for metastatic HG-NENs after progression on platinum based therapy and available chemotherapy is of limited benefit. Given the promising activ... read more here.
Keywords: patients previously; monotherapy patients; pembrolizumab monotherapy; treated metastatic ... See more keywords
Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of General Medicine"
DOI: 10.2147/ijgm.s379269
Abstract: Objective This study was to investigate the effectiveness and tolerability of anlotinib plus PD-1 inhibitors for patients with previously treated metastatic soft tissue sarcoma (STS). Methods Patients with previously treated metastatic STS who were administered… read more here.
Keywords: anlotinib plus; plus inhibitors; previously treated; patients previously ... See more keywords
Meta-analysis of pazopanib and trabectedin effectiveness in previously treated metastatic synovial sarcoma (second-line setting and beyond).
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0348
Abstract: Background: This study examined the efficacy/effectiveness of pazopanib and trabectedin in previously treated metastatic synovial sarcoma (mSS). Materials & methods: A literature search identified studies (2002-2019) reporting outcomes of pazopanib and trabectedin in previously treated mSS,… read more here.
Keywords: pazopanib; pazopanib trabectedin; previously treated; metastatic synovial ... See more keywords